Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma

Liu, Liting; Chua, Melvin L.K.; Tao, Yungan; Tang, Lin‐Quan

doi:10.1186/s40880-019-0398-0

Cited by 5 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the initial EBV DNA load was related to N classification that is patients with a higher initial EBV load had a higher N classification. This finding was consistent to previous studies [ 4 , 18 ]. In addition, we found that EBV DNA load was associated with a variety of lymphocyte subsets, especially CD3+ percentage and CD3 + CD8+ percentage.…”

Section: Discussionsupporting

confidence: 94%

Circulating lymphocyte subsets are prognostic factors in patients with nasopharyngeal carcinoma

et al. 2022

View full text Add to dashboard Cite

Background Nasopharyngeal carcinoma (NPC) is a geographically and racially variable disease that has a high incidence in Southeast China. According to previous studies on tumor immunity, we compared multiple clinical parameters and blood indexes with outcomes regarding to Epstein-Barr virus (EBV) status in NPC patients. Methods According to the EBV load at diagnosis, 220 NPC patients who received concurrent chemoradiotherapy (CRT) were divided into two groups: EBV DNA ≥ 1500 copies/mL and EBV DNA < 1500 copies/mL, respectively. We compared clinical parameters with peripheral blood mononuclear cells, lymphocyte subsets and biochemical indexes. We also analyzed distant metastases and the overall survival rate regarding to these characteristics. Results In most cases, the two groups showed the same trends. Most blood indexes were decreased during CRT and the decrease of the absolute count was more significant than the percentage. Patients with younger age showed the higher CD3+ and CD3 + CD8+ percentages. Patients whose EBV DNA ≥ 1500 copies/mL showed a higher N classification than those with EBV DNA < 1500 copies/mL at first diagnosis. Within patients with EBV DNA ≥ 1500 copies/mL, a higher CD3 + CD8+ percentage or lower CD3-CD56+ percentage had better OS rates, and the CD3 + CD8+ percentage was an independent prognostic factor by multivariate survival analyses. Conclusions CRT caused an overall decrease of blood cells in NPC patients. Among all the blood indexes, the CD3 + CD8+ percentage showed a correlation with age and was an independent prognostic factor in patients with EBV DNA ≥ 1500 copies/mL at first diagnosis, which is worthy for further large cohort study.

show abstract

Section: Discussionsupporting

confidence: 94%

Circulating lymphocyte subsets are prognostic factors in patients with nasopharyngeal carcinoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Apart from the initial assessment, post-treatment EBV DNA response may be useful for predicting outcome [26,27]. A study monitoring serial EBV DNA concentrations at diagnosis, during treatment, and after treatment showed that post-treatment levels are more predictive of relapse than pre-treatment levels [28].…”

Section: Ebv Dnamentioning

confidence: 99%

Emerging radiotherapy technologies and trends in nasopharyngeal cancer

Tseng

Leong

et al. 2020

Cancer Communications

View full text Add to dashboard Cite

Technology has always driven advances in radiotherapy treatment. In this review, we describe the main technological advances in radiotherapy over the past decades for the treatment of nasopharyngeal cancer (NPC) and highlight some of the pressing issues and challenges that remain. We aim to identify emerging trends in radiation medicine. These include advances in personalized medicine and advanced imaging modalities, standardization of planning and delineation, assessment of treatment response and adaptive re‐planning, impact of particle therapy, and role of artificial intelligence or automation in clinical care. In conclusion, we expect significant improvement in the therapeutic ratio of radiotherapy treatment for NPC over the next decade.

show abstract

“…Thus, huge leaps with technological advances in RT delivery over the past decades have led to substantial improvements in tumor control, while reducing debilitating late RT‐induced complications [1, 2]. Innovations in this space continue to drive the enhancement of the therapeutic ratio of RT, with the goal of enhancing the quality of life (QoL) among long‐term survivors [3]. Therefore, there has not been any compelling reason to disrupt this time‐honored convention of employing RT as the standard of care in NPC.…”

mentioning

confidence: 99%

Surgery as an alternative to radiotherapy in early‐stage nasopharyngeal carcinoma: innovation at the expense of uncertainty

Chua

2020

Cancer Communications

View full text Add to dashboard Cite

Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma

Cited by 5 publications

References 23 publications

Circulating lymphocyte subsets are prognostic factors in patients with nasopharyngeal carcinoma

Circulating lymphocyte subsets are prognostic factors in patients with nasopharyngeal carcinoma

Emerging radiotherapy technologies and trends in nasopharyngeal cancer

Surgery as an alternative to radiotherapy in early‐stage nasopharyngeal carcinoma: innovation at the expense of uncertainty

Contact Info

Product

Resources

About